Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK117 and AK112 with Chemotherapy in Previously Untreated Metastatic Triple-Negative Breast Cancer
NCT05227664Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab, ivonescimab in triple-negative breast cancer (TNBC), sponsored by Akeso, Inc.. Started Mar 2022; status: active, not recruiting.
02
Drugs
ligufalimabivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05227664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227664.